GlassScriptPhysician profile
Brigitte Pinkerton
NPI 1578283628
$7,552.03
in general payments reported to CMS, 2019-2025
43 companies · $395 in 2025
The $395 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $828 · 2023: $2,844 · 2024: $3,486 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,635 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,634.52 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,078.73 | 2023-2024 | Austedo Xr, Austedo, Ajovy |
| Novartis Pharmaceuticals Corporation | $540.31 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $471.44 | 2024-2025 | Cobenfy, Zeposia |
| Abbvie INC. | $450.53 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $449.10 | 2023-2024 | |
| Sk Life Science, INC. | $417.48 | 2023-2024 | |
| Pfizer INC. | $359.97 | 2024 | |
| Neurelis, INC. | $337.19 | 2022-2024 | Valtoco |
| Neurocrine Biosciences, INC. | $302.75 | 2022-2023 | Ingrezza, Ongentys |
| Celgene Corporation | $296.34 | 2022-2024 | Zeposia |
| Lilly USA, LLC | $272.32 | 2023-2024 | Amyvid, Emgality, Reyvow |
| Genentech USA, INC. | $259.05 | 2022-2024 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Acadia Pharmaceuticals INC | $236.93 | 2023-2024 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $229.58 | 2024 | Rexulti |
| Ucb, INC. | $224.21 | 2022-2024 | Nayzilam, Briviact |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $213.80 | 2022-2024 | Vyepti, Rexulti |
| Averitas Pharma INC. | $147.49 | 2025 | Qutenza |
| Harmony Biosciences LLC | $147.47 | 2022-2024 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $131.13 | 2023-2024 | Hyqvia, Gammagard |
| Emd Serono, INC. | $123.40 | 2023-2024 | Mavenclad |
| Idorsia Pharmaceuticals US INC | $105.07 | 2022-2023 | Quviviq |
| Eisai INC. | $82.13 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $81.30 | 2022 | |
| Octapharma USA, INC. | $80.00 | 2022-2024 | Panzyga, Octagam Immune Globulin (Human) |
| Grifols USA, LLC | $66.32 | 2023-2024 | Gamunex-C |
| Ani Pharmaceuticals, INC. | $46.36 | 2024 | Purified Cortrophin Gel |
| Amgen INC. | $41.45 | 2022 | |
| Azurity Pharmaceuticals, INC. | $38.22 | 2024 | Horizant |
| Acorda Therapeutics, INC | $34.40 | 2024 | Inbrija |
| Impel Pharmaceuticals INC. | $32.62 | 2022-2023 | Trudhesa |
| Merz Pharmaceuticals, LLC | $31.54 | 2024 | Ampyra, Xeomin |
| Kyowa Kirin, INC. | $23.41 | 2024 | Nourianz |
| Inspire Medical Systems, INC. | $22.70 | 2023 | Inspire |
| Csl Behring | $22.51 | 2024 | Hizentra |
| Grt US Holding, INC. | $20.59 | 2022 | |
| Mdd US Operations, LLC | $18.86 | 2024 | Gocovri |
| Amneal Pharmaceuticals LLC | $18.39 | 2023 | Rytary |
| Merck Sharp & Dohme LLC | $18.08 | 2022 | |
| Collegium Pharmaceutical, INC. | $17.72 | 2022 | |
| Axsome Therapeutics, INC. | $17.64 | 2024 | Sunosi |
| Novo Nordisk INC | $16.76 | 2023 | Wegovy |
| Sumitomo Pharma America, INC. | $13.45 | 2023 | Aptiom |
| Aprecia Pharmaceuticals, LLC | $13.29 | 2023 | Spritam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brigitte Pinkerton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.